CEO Of Malaysia’s BiotechCorp Says Country To Be Global Player
This article was originally published in PharmAsia News
The head of Malaysian Biotechnology Corp. says his country is on a path toward becoming a significant global player by 2018. CEO Datuk Iskandar Mizal Mahmood said at BioMalaysia 2008 in Kuala Lumpur when talking about the services of his agency, which serves as government promoter of biotechnology industry in the Malaysia, more money needs to be put into high-quality training of Malaysians who will be needed to do the work. Officers of foreign partners confirmed Malaysia's biotech pace, one from India suggesting the Malaysian government should hold down the personal income tax levied on the foreign professionals who will be needed to provide that training. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.